Aqtual to Present New Rheumatoid Arthritis Therapy Selection Data at CCR East 2024

HAYWARD, Calif., May 9, 2024 -- Aqtual, Inc., a precision medicine company specializing in cell-free DNA technology to develop treatments for chronic diseases and cancer, has announced its participation in the Congress of Clinical Rheumatology 2024 meeting in Destin, Florida, from May 9-12, 2024. The company will present two significant posters at this event.

The first poster reveals proof-of-concept data for an innovative blood-based therapy selection test. This test aims to predict how patients with rheumatoid arthritis (RA) will respond to treatments. The second poster showcases the PRIMA-102 study, Aqtual's ongoing prospective observational clinical trial, which now includes over 800 participants. This extensive multicenter study supports the development of their new testing methods.

Professor Jeff Curtis from the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, a senior author on the proof-of-concept poster, highlighted the need for precision medicine in RA treatment. He explained that many patients often have to try various drugs before finding an effective treatment, leading to prolonged pain and potential long-term damage, as well as significant healthcare costs due to ineffective medications.

The proof-of-concept data emphasizes the potential of Aqtual's blood-based test to accurately gauge patient responses to specific treatments. This advanced classifier shows promise in differentiating between patients who respond to two major drug classes—TNFa inhibitors and JAK inhibitors—thus enabling more accurate and effective treatment choices.

Diana Abdueva, Ph.D., co-founder and CEO of Aqtual, stated that the data presented at the Congress of Clinical Rheumatology East 2024 is a crucial step in the development of Aqtual's first therapy selection test. This tool is expected to aid rheumatologists in selecting appropriate therapies and helping RA patients achieve better disease control. Abdueva added that their results confirm the classifier's ability to predict treatment responses and its strong correlation with RA tissue pathology.

The posters presented by Aqtual include:
1. A Novel Blood-based Assay that Predicts Clinical Response to TNFa or JAKi in Patients with Rheumatoid Arthritis
2. PRIMA-102: Predicting Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients Using a Blood-Based Cell-free DNA Classifier

About Aqtual, Inc.
Aqtual, Inc. is a company at the forefront of precision medicine, focused on developing products for the management of chronic diseases and oncology. Their proprietary cell-free DNA platform analyzes protein regulation, epigenetics, and transcriptomics using only cell-free DNA fragments found in blood. This technology allows efficient and robust real-time analysis of disease and treatment, surpassing the limitations of previous cell-free DNA methods.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!